The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach
Open accessAbstract
Background: Diagnosis of dementia with Lewy bodies (DLB) is challenging, largely due to a lack of diagnostic tools. Cerebrospinal fluid (CSF) biomarkers have been proven useful in Alzheimer’s disease (AD) diagnosis. Here, we aimed to identify novel CSF biomarkers for DLB using a high-throughput proteomic approach. Methods: We applied liquid chromatography/tandem mass spectrometry with label-free quantification to identify biomarker candidates to individual CSF samples from a well-characterized cohort comprising patients with DLB (n = 20) and controls (n = 20). Validation was performed using (1) the identical proteomic workflow in an independent cohort (n = 30), (2) proteomic data from patients with related neurodegenerative diseases (n = 149) and (3) orthogonal techniques in an extended cohort consisting of DLB patients and controls (n = 76). Additionally, we utilized random forest analysis to identify the subset of candidate markers that best distinguished DLB from all other groups. Results: In total, we identified 1995 proteins. In the discovery cohort, 69 proteins were differentially expressed in DLB compared to controls (p < 0.05). Independent cohort replication confirmed VGF, SCG2, NPTX2, NPTXR, PDYN and PCSK1N as candidate biomarkers for DLB. The downregulation of the candidate biomarkers was somewhat more pronounced in DLB in comparison with related neurodegenerative diseases. Using random forest analysis, we identified a panel of VGF, SCG2 and PDYN to best differentiate between DLB and other clinical groups (accuracy: 0.82 (95%CI: 0.75–0.89)). Moreover, we confirmed the decrease of VGF and NPTX2 in DLB by ELISA and SRM methods. Low CSF levels of all biomarker candidates, except PCSK1N, were associated with more pronounced cognitive decline (0.37 < r < 0.56, all p < 0.01). Conclusion: We identified and validated six novel CSF biomarkers for DLB. These biomarkers, particularly when used as a panel, show promise to improve diagnostic accuracy and strengthen the importance of synaptic dysfunction in the pathophysiology of DLB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Fig. 5 Validation of candidate biomarkers. a Differences in levels of candidate biomarkers between DLB and related neurodegenerative diseases. All protein levels were Z transformed according to the mean and standard deviation in controls, dotted line represents average protein levels for the control group. For PDYN, 4 outliers (z-score > 20) were illustrated in a box. Please note that the low variation in PDYN levels in AD patients is caused by lack of a measurable concentration.Differences were assessed with GLM corrected for age and a FDR correction was applied. * p < 0.05, ** p < 0.01, *** p < 0.001. b Validation of VGF and NPTX2 using orthogonal analytical methods. Levels of VGF373–417 (pmol/ml) were determined by ELISA, levels of VGF [LH/ratio] were determined with SRM and levels of NPTX2 (pg/ml) were determined with ELISA in CSF samples from DLB patients (n = 48) and controls (n = 28). The line through the middle of the boxes corresponds to the median and the lower and the upper lines to the 25th and 75th percentile, respectively. The whiskers extend from the 5th percentile on the bottom to the 95th percentile on top. Differences between DLB patients and controls were assessed with GLM. * p < 0.05, ** p < 0.01, *** p < 0.001. Abbreviations: AD, Alzheimer’s disease; DLB, Dementia with Lewy bodies; ELISA, enzyme-linked immunosorbent assays; FTD, frontotemporal dementia; NPTX2, Neuronal pentraxin 2; NPTXR, Neuronal pentraxin receptor, PCSK1N, ProSAAS; PD, Parkinson’s disease; PDYN, Proenkephalin-B; SCG2, Secretogranin-2; SRM, selected reaction monitoring; VGF, Neurosecretory protein VGF](https://figures.cochat.ai/paper-figures/b5a7a5983f7d487696bee67561837ae7/identification-of-novel-cerebrospinal-fluid-biomarker-candidates-for-dementia-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The decrease of neuronal pentraxins in the Lewy body dementias groups corroborates our previous findings [41] and could be due to the accumulation of these proteins in Lewy bodies, as it has been found for NPTX2 in Parkinson’s disease [67].”
The cited source says what the claim attributes to it.
In the citing paper
“Several proteomics studies have identified neuronal pentraxins to be deregulated in the CSF of patients with neurodegenerative diseases [22, 41, 42].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo
Rockenstein, E., Nuber, S., Overk, C. R., Ubhi, K., Mante, M., Patrick, C., Adame, A., Trejo-Morales, M., Gerez, J., Picotti, P., et al. (2014) · Brain · doi:10.1093/brain/awu057 · Cited by 238
RetractedBreiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
Cox, J., & Mann, M. (2008) · Nature Biotechnology · doi:10.1038/nbt.1511 · Cited by 14,855
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Mass spectrometry-based proteomics
Aebersold, R., & Mann, M. (2003) · Nature · doi:10.1038/nature01511 · Cited by 6,955
Cox, J., Hein, M. Y., Luber, C. A., Paron, I., Nagaraj, N., & Mann, M. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.031591 · Cited by 5,180
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
International Classification of Sleep Disorders-Third Edition
Sateia, M. J. (2014) · Chest · doi:10.1378/chest.14-0970 · Cited by 3,860
Cited by
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
Targeting synapse function and loss for treatment of neurodegenerative diseases
Dejanovic, B., Sheng, M., & Hanson, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00823-1 · Cited by 191
Zhou, J., Wade, S. D., Graykowski, D., Xiao, M.-F., Zhao, B., Giannini, L. A. A., Hanson, J. E., van Swieten, J. C., Sheng, M., Worley, P. F., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf0141 · Cited by 152
Self-citationVGF as a biomarker and therapeutic target in neurodegenerative and psychiatric diseases
Quinn, J. P., Kandigian, S. E., Trombetta, B. A., Arnold, S. E., & Carlyle, B. C. (2021) · Brain Communications · doi:10.1093/braincomms/fcab261 · Cited by 139
Brockmann, K., Quadalti, C., Lerche, S., Rossi, M., Wurster, I., Baiardi, S., Röeben, B., Mammana, A., Zimmermann, M., Hauser, A., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01276-6 · Cited by 138
Metadata
- Authors
- van Steenoven, I., Koel-Simmelink, M. J. A., Vergouw, L. J. M., Tijms, B. M., Piersma, S. R., Pham, T. V., Bridel, C., Ferri, G.-L., Cocco, C., Noli, B., Worley, P. F., Xiao, M.-F., Xu, D., Oeckl, P., Otto, M., van der Flier, W. M., de Jong, F. J., Jimenez, C. R., Lemstra, A. W., & Teunissen, C. E.
- Affiliations
- Amsterdam Neuroscience (NL)
- Erasmus MC (NL)
- Amsterdam University Medical Centers (NL)
- University of Cagliari (IT)
- Johns Hopkins University (US)
- University Hospital Ulm (DE)
- Corresponding author
- van Steenoven, Inger
- ORCID
- Venue
- Molecular Neurodegeneration
- Published
- 2020-06-18
- Volume
- 15
- Issue
- 1
- Pages
- 36-36
- ISSN
- 1750-1326 (ISSN-L)
- PMC
- PMC7301448
- OpenAlex
- W3036301115
- Cited by
- 83
- References
- 57
- Citations by year
- 2026: 3 · 2025: 20 · 2024: 11 · 2023: 16 · 2022: 15 · 2021: 15 · 2020: 3
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Neurodegeneration (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion, cc-by)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Alzheimer Nederland (Not applicable)
- Stichting VUmc Fonds (Not applicable)
- Stichting Dioraphte (Not applicable)
- ZonMw (733050509, 733050102, 733050206, 91116017)
- Bundesministerium für Bildung und Forschung (01GI1007A)
- EU Joint Programme – Neurodegenerative Disease Research (01ED1512)
- Deutsche Forschungsgemeinschaft (SFB 1237)
- Regione Autonoma della Sardegna (2012-CRP-60834)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Keywords
- dementia with Lewy bodies, cerebrospinal fluid biomarkers, proteomics, VGF, secretogranin II, NPTX2, prodynorphin, diagnostic biomarker panel, cognitive decline, synaptic dysfunction, neurodegenerative diseases
- MeSH terms
- Aged, Alzheimer Disease, Dementia, Female, Humans, Male, Middle Aged, Peptide Fragments, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Lewy Body Disease, Proteomics, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. https://app.cochat.ai/papers/10.1186/s13024-020-00388-2
- The paper
- van Steenoven, I., Koel-Simmelink, M. J. A., Vergouw, L. J. M., Tijms, B. M., Piersma, S. R., Pham, T. V., Bridel, C., Ferri, G.-L., Cocco, C., Noli, B., Worley, P. F., Xiao, M.-F., Xu, D., Oeckl, P., Otto, M., van der Flier, W. M., de Jong, F. J., Jimenez, C. R., Lemstra, A. W., & Teunissen, C. E. (2020). Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-020-00388-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.